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In a previous health technology assessment, the
cost-utility of VNS therapy was calculated as
£28,849 per quality-adjusted life year (QALY)
gained.1 This economic model assumed that the
device’s life expectancy was at best 5 years, and
that the number needed to treat was 6 to produce
one responder (with a 50% or more reduction in
seizure frequency). Sensitivity analysis concluded
that the economic argument against VNS therapy
was weak, although the baseline cost-utility ratio
was at the upper level of what is widely accepted as
reasonable.1
Recently, technical improvements have increased
device battery life expectancy to at least 6 yearsTable 1 Updated cost-utility model of VNS for medically r
Model parameter
(data source where relevant)
Baseline L
b
VNS cost per device (Cyberonics Inc.) 5500 5
Costs averted per year of successful
implantation1
954 9
Number-needed to treat to reduce
seizure frequency by 50% in one
person2
2 2
QALYS gained per year of effective
use per person1
0.285 0
Device life expectancy2 6 8
Cost per QALY gained for a programme of
VNS implantation to benefit at
least one person
4423 3
Baseline model assumes–—£678 per hour of neurosurgical operating t
£682 per day in hospital, similar theatre and in-patient stay for e
Infection rate of 1.1% with cost of treating infection of £4774. Costs
locally published health statistics, other data from Ref.1.
1059-1311/$ — see front matter # 2007 British Epilepsy Association
doi:10.1016/j.seizure.2007.10.005(with standard stimulation parameters of 20 Hz,
500 ms pulse width, 2 mA output current, 4 V lead
impedance), and 8 years is technically realistic.2
Device costs have remained stable. In addition,
follow-up data repeatedly demonstrates reductions
in seizure frequency of between 40% pooled data
from EO1, EO2, EO3 and EO4 trials,2 to 55%3 or 58%4
in larger follow-up studies. In this more pragmatic
setting, the number need to treat to obtain one
responder could be as low as 2.
A re-appraisal of cost-utility is therefore overdue
(Table 1), and the new baseline estimate is now
significantly less at £4423 per QALY gained.
As few patients ever experience complete seizure
freedom with VNS therapy, acceptance of its role is
not universal, although VNS therapy is recom-
mended by national health technology assessment
organisations such as NICE in the UK.5 For those who
are of the opinion that VNS therapy has a major
palliative role, this therapeutic effect appears to
have a greatly improved cost-utility ratio which is
robust even with conservative assumptions about
device cost, battery life expectancy and number
needed to treat (Table 1).efractory epilepsy (all costs UK£, 2006 prices)
ong-life
attery
Less effective
device
Less effective,
longer battery
Original
paper1
500 5,500 4500 5,500
54 954 954 745
4 4 6
.285 0.285 0.285 0.285
6 8 5
002 11,819 8869 22,849
heatre, 1 h operating time per implant, day case procedure with
xplantation of infected device and explantation rate of 2.7%.
averted per successful implantation £954 per annum. Costs from
. Published by Elsevier Ltd. All rights reserved.
388 Letter to the EditorThis updated economic analysis suggests that
device cost is no longer a rational argument against
the adoption of VNS therapy, as the cost-per-QALY
gained is now within acceptable, albeit arbitrary,
limits employed by the health technology assess-
ment communities. Acceptable levels of cost-effec-
tiveness have been established in the past for VNS
therapy using the different economic approach of
cost-minimisation analysis.6,7 In these studies hos-
pital costs6 and epilepsy-related direct medical
costs7 were reduced for medically refractory epi-
lepsy treated with VNS.
Professional and lay advocates for people with
medically refractory epilepsy could use this infor-
mation to argue more effectively for resources to
treat their patients.Conflict of interest
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